Bausch + Lomb Corporation

NYSE:BLCO

Medical - Instruments & Supplies

Healthcare
$20.95 +0.27%

+$0.04 today

Market cap
$7.49B
Beta
0.57
P/E (TTM)
-24.2
EPS (TTM)
-$0.62
52W Low $11.58High $18.92

Volume 0.51M

Average 0.46M

BLCO Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Bausch + Lomb CorporationNYSE: BLCO

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 59.1%

Gross margin was 59.1% in Q2 FY2026, up 5.4 pp from a year earlier. On a trailing-twelve-month basis it was 57.2%, up 0.3 pp year over year. Over 3 fiscal years it narrowed by 4.9 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
59.1%+2.5 pp QoQ
Last fiscal yearDec 2025
54.8%-6.2 pp YoY
LTMJun 2026
57.2%+0.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+5.4 pp——
1 year-6.2 pp——
3 years-4.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
54.8%
Year-over-year change
-6.2pp

Gross Margin vs competitors

How BLCO compares with its peers on the latest reported figures

  • BLCO's LTM Jun 2026 gross margin of 57.2% is the 5th highest of the 9 companies compared; the peer median is 66.4%.
  • Its year-over-year change of +0.3 pp is the 4th highest of 9, against a peer median of -1.1 pp.
  • Over three fiscal years its change of -4.9 pp compares with a peer median of +2.1 pp.
BLCO Competitors Peer median
Gross Margin for BLCO and competitors
Company Period LTM level YoY 3-year change
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 202699.6% -0.4 pp+4.8 pp
TGTXTG Therapeutics, Inc.LTM Sep 202682.7% -2.6 pp-6.8 pp
PTCTPTC Therapeutics, Inc.LTM Jun 202682.1% -14.9 pp+2.2 pp
GKOSGlaukos CorporationLTM Jun 202679.1% +2.8 pp+1.9 pp
BLCOBausch + Lomb CorporationLTM Jun 202657.2% +0.3 pp-4.9 pp
TFXTeleflex IncorporatedLTM Jun 202653.8% -1.8 pp+1.4 pp
MMSIMerit Medical Systems, Inc.LTM Sep 202649.4% +0.9 pp+3.6 pp
OSCROscar Health, Inc.LTM Jun 202644.9% +9.0 pp-85.6 pp
CRSPCRISPR Therapeutics AGLTM Sep 2026-558.9% -202.1 pp+18649.7 pp
PCVXVaxcyte, Inc.FY2025— ——
Peer median (excluding BLCO) 66.4%-1.1 pp+2.1 pp

Competitors are the stored peer set for BLCO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.77B3.77B4.15B4.79B5.1B
Cost of Revenue1.47B1.52B1.64B1.87B2.31B
Gross Profit2.3B2.25B2.5B2.92B2.79B
Gross Margin61.0%59.7%60.4%60.9%54.8%
Research & Development271M307M324M343M371M
Selling, General & Admin1.39B1.48B1.74B2.08B2.23B
Operating Expenses1.97B2.04B2.37B2.76B2.61B
Depreciation & Amortization415M379M382M436M421M
EBITDA733M598M499M601M535M
EBITDA Margin19.5%15.9%12.0%12.5%10.5%
Operating Income329M207M130M162M188M
Operating Margin8.7%5.5%3.1%3.4%3.7%
Interest Income06M15M15M12M
Interest Expense0146M283M399M431M
Other Income / Expenses(11M)(134M)(296M)(396M)(505M)
Income Before Tax318M73M(166M)(234M)(317M)
Pre-Tax Margin8.4%1.9%-4.0%-4.9%-6.2%
Income Tax Expense125M58M82M71M35M
Net Income182M6M(260M)(317M)(360M)
Net Margin4.8%0.2%-6.3%-6.6%-7.1%
EPS (Basic)0.520.04(0.74)(0.90)(1.02)
EPS (Diluted)0.520.04(0.74)(0.90)(1.02)
Weighted Avg Shares350M350M350.5M351.8M353.8M
Weighted Avg Shares (Diluted)350M350M350.5M351.8M353.8M

Bausch + Lomb Corporation

NYSE:BLCO

Intrinsic Alpha fair value

Locked

Current Price

$20.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.